Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01324947 · OUTCOME

Kaplan-Meier Estimate for Overall Survival

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma · Source last updated 2019-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
weeks
Interval / dispersion
95% Confidence Interval
Time frame
From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.

What was measured

Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.

Analysis population: Intent to Treat population included all participants enrolled into the study

Groups in this outcome

Pomalidomide

Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pomalidomide74

Reported measurements

Source class 1
Values in weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pomalidomide33.6Not reported26.466.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        26.4
        upper Limit
        66.3
        value
        33.6
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    units
    Participants
description
Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
dispersion Type
95% Confidence Interval
groups
  1. description
    Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
    id
    OG000
    title
    Pomalidomide
param Type
MEDIAN
population Description
Intent to Treat population included all participants enrolled into the study
reporting Status
POSTED
time Frame
From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.
title
Kaplan-Meier Estimate for Overall Survival
type
SECONDARY
unit Of Measure
weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice